Suppression of prolactin expression by cabergoline requires prolactin regulatory element-binding protein (PREB) in GH3 cells

Hormone and Metabolic Research

Volumn 42, Issue 8, 2010, Pages 557-561

  Zhang, W ^a,b   Murao, K ^b   Imachi, H ^b   Iwama, H ^b   Chen, K ^b   Fei, Z ^a   Zhang, X ^a   Ishida, T ^b   Tamiya, T ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

cabergoline; pituitary; PREB; prolactinoma; transcription

Indexed keywords

BINDING PROTEIN; CABERGOLINE; PROLACTIN; PROLACTIN REGULATORY ELEMENT BINDING PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ERGOLINE DERIVATIVE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PREB PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; CELL CULTURE; CELL STRAIN GH3; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; DOWN REGULATION; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PROMOTER REGION; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; ERGOLINES; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; PROLACTIN; PROLACTINOMA; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 77954240604     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1252064     Document Type: Article

References (18)

1. Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet 1998 352 1455-1461
2. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary 2005 8 43-52
3. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003 349 2023-2033
4. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001 86 5256-5261
5. Fliss MS, Hinkle PM, Bancroft C. Expression cloning and characterization of PREB (prolactin regulatory element binding), a novel WD motif DNA-binding protein with a capacity to regulate prolactin promoter activity. Mol Endocrinol 1999 13 644-657
6. Taylor Clelland CL, Levy B, McKie JM, Duncan AM, Hirschhorn K, Bancroft C. Cloning and characterization of human PREB; a gene that maps to a genomic region associated with trisomy 2p syndrome. Mamm Genome 2000 11 675-681
7. Neer EJ, Schmidt CJ, Nambudripad R, Smith TF. The ancient regulatory-protein family of WD-repeat proteins. Nature 1994 371 297-300
8. Ohtsuka S, Murao K, Imachi H, Cao WM, Yu X, Li J, Iwama H, Wong NC, Bancroft C, Ishida T. Prolactin regulatory element binding protein as a potential transcriptional factor for the insulin gene in response to glucose stimulation. Diabetologia 2006 49 1599-1607
9. Murao K, Imachi H, Yu X, Cao WM, Muraoka T, Dobashi H, Hosomi N, Haba R, Iwama H, Ishida T. The transcriptional factor prolactin regulatory element-binding protein mediates the gene transcription of adrenal scavenger receptor class B type I via 3,5-cyclic adenosine 5-monophosphate. Endocrinology 2008 149 6103-6112
10. Imachi H, Murao K, Cao WM, Muraoka T, Nishiuchi T, Dobashi H, Hosomi N, Iwama H, Ishida T. The prolactin regulatory element-binding regulates of the 11beta-hydroxylase gene. Biochem Biophys Res Commun 2008 376 531-535
11. Murao K, Terpstra V, Green SR, Kondratenko N, Steinberg D, Quehenberger O. Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. J Biol Chem 1997 272 17551-17557
12. Murao K, Imachi H, Cao WM, Yu X, Tokumitsu H, Inuzuka H, Wong NC, Shupnik MA, Kobayashi R, Ishida T. Role of calcium-calmodulin-dependent protein kinase cascade in thyrotropin (TSH)-releasing hormone induction of TSH and prolactin gene expression. Endocrinology 2004 145 4846-4852
13. 2+-dependent effect of D2 dopaminergic receptor activation in rat lactotroph cells. J Biol Chem 1988 263 10127-10134
14. Liu JC, Baker RE, Sun C, Sundmark VC, Elsholtz HP. Activation of Go-coupled dopamine D2 receptors inhibits ERK1/ERK2 in pituitary cells. A key step in the transcriptional suppression of the prolactin gene. J Biol Chem 2002 277 35819-35825
15. DeCamilli P, Macconi D, Spada A. Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 1979 278 252-254
16. Senogles SE. The D2 dopamine receptor isoforms signal through distinct Gia proteins to inhibit adenylyl cyclase. J Biol Chem 1994 269 23120-23127
17. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001 22 724-763
18. Kanasaki H, Fukunaga K, Takahashi K, Miyazaki K, Miyamoto E. Mitogen-activated protein kinase activation by stimulation with thyrotropin-releasing hormone in rat pituitary GH3 cells. Biol Reprod 1999 61 319-325